Readystate Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Readystate Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-952,165	Closed	-$31.9M	–	1015
2026 Q1	$31.9M	Buy	952,165 +77,718	+9%	+$3.05M	1.43%	11
2025 Q4	$40.5M	Buy	874,447 +668,640	+325%	+$36.7M	1.64%	10
2025 Q3	$13.9M	Sell	205,807 -187,002	-48%	-$13.9M	0.59%	48
2025 Q2	$32.9M	Buy	392,809 +293,387	+295%	+$22M	1.01%	19
2025 Q1	$7.1M	Buy	99,422 +49,422	+99%	+$2.41M	0.24%	75
2024 Q4	$2.25M	Buy	+50,000	New	+$2.59M	0.07%	284

Readystate Asset Management's SLNO Position: Q2 2026 in Review

Readystate Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 952,165 shares — an estimated $31.9M sold.

Readystate Asset Management first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $40.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Readystate Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Readystate Asset Management sold 952,165 Soleno Therapeutics shares in Q2 2026, an estimated $31.9M.
Readystate Asset Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
Readystate Asset Management's Soleno Therapeutics position peaked at $40.5M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.